Construction of a dietary-cure Saccharomyces cerevisiae expressing long-acting glucagon-like peptide-1 and investigation of its hypoglycemic activity in type 2 diabetes mellitus mouse model

  • Pingzhe Jiang
  • Chao Ma
  • Junfeng Hao
  • Yike Han
  • Minggang LiEmail author


Bio-drug is a new type of beneficial biology expressing therapeutic peptides (protein) as orally administrated medicine to treat diseases, in particular, chronic diseases like diabetes. In order to develop recombinant yeast strains as a bio-drug which could effectively ameliorate type 2 diabetes, an integrating expression vector pNK1-PGK that could successfully express green fluorescent protein (GFP) in Saccharomyces cerevisiae was constructed to demonstrate the normality of the function. A pNK1-PGK vector, which expresses 10 tandem repeats of long-acting glucagon-like peptide-1(10laGLP-1), was cloned and then transformed into the S. cerevisiae INVSc1. The long-acting GLP-1 hypoglycemic yeast (LHY168) that grew rapidly and expressed 10laGLP-1 stably was screened by uracil-deficient plates and Western blot. The expression quantity of 10laGLP-1 reached 1.56 mg/g cell wet weight. Moreover, the oral administration of LHY168 significantly declined the blood glucose in type 2 diabetic mice that were constructed through co-induction of streptozotocin (STZ) and high-fat and high-sugar diet.


Long-acting GLP-1 hypoglycemic yeast (LHY) long-acting glucagon-like peptide-1(10laGLP-1) recombinant yeast type 2 diabetes 



This work is supported by the National Natural Science Foundation of China (31771066) and the Key Technologies R&D Program of Tianjin (18YFZCSY00030 and 18YFZCNC01200).


  1. Ahren B 1995 Insulinotropic action of truncated glucagon-like peptide-1 in mice. Acta Physiol. Scand. 153 205–206CrossRefGoogle Scholar
  2. Amberg DC 2009 Experimental guide to the method of yeast genetics (The Science Publishing Company)Google Scholar
  3. Baggio LL and Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132 2131–2157CrossRefGoogle Scholar
  4. Bonora S, et al. 2012 Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. Infection 40 69–75CrossRefGoogle Scholar
  5. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB and Petersen JS 2005 The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330 577–584CrossRefGoogle Scholar
  6. Brownlee M 2001 Biochemistry and molecular cell biology of diabetic complications. Nature 414 813–820CrossRefGoogle Scholar
  7. Bussineau CM and Shuster JR 1994 Genetic stability of protein expression systems in yeast. Dev. Biol. Stand. 83 13–19PubMedGoogle Scholar
  8. Dai Z, Wang B, Liu Y, Shi M, Wang D, Zhang X, Liu T, Huang L and Zhang X 2014 Producing aglycons of ginsenosides in bakers’ yeast. Sci. Rep. 4 3698CrossRefGoogle Scholar
  9. Danaei G, et al. 2011 National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378 31–40CrossRefGoogle Scholar
  10. Deacon CF 2007 Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes. Metab. 9 Suppl 1 23–31CrossRefGoogle Scholar
  11. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM and Perfetti R 2003 Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 5149–5158CrossRefGoogle Scholar
  12. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B and Group L-S 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 473–481CrossRefGoogle Scholar
  13. Holst JJ, Orskov C, Nielsen OV and Schwartz TW 1987 Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211 169–174CrossRefGoogle Scholar
  14. Kieffer TJ, McIntosh CH and Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 3585–3596CrossRefGoogle Scholar
  15. Lopes TS, de Wijs IJ, Steenhauer SI, Verbakel J and Planta RJ 1996 Factors affecting the mitotic stability of high-copy-number integration into the ribosomal DNA of Saccharomyces cerevisiae. Yeast 12 467–477CrossRefGoogle Scholar
  16. Ma B, Tu P, Zhao X, Zhang Y, Wang Y, Ma C, Ji Y, Li X, Abbas SA and Li M 2013 Expression and purification of optimized rolGLP-1, a novel GLP-1 analog, in Escherichia coli BL21(DE3) and its good glucoregulatory effect on type 2 diabetic mice. Curr. Pharm. Biotechnol. 14 985–994CrossRefGoogle Scholar
  17. Ni Z, et al. 2017 Pharmacological effects and pharmacokinetic properties of a dual-function peptide 5rolGLP-HV. Appl. Biochem. Biotechnol. 181 483–494CrossRefGoogle Scholar
  18. Ni Z, et al. 2016 Construction of a fusion peptide 5rolGLP-HV and analysis of its therapeutic effect on type 2 diabetes mellitus and thrombosis in mice. Appl. Biochem. Biotechnol. 179 59–74CrossRefGoogle Scholar
  19. Perfetti R and Merkel P 2000 Glucagon-like peptide-1 a major regulator of pancreatic beta-cell function. Eur. J. Endocrinol. 143 717–725CrossRefGoogle Scholar
  20. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K and Trautmann M 2010 Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33 1173–1175CrossRefGoogle Scholar
  21. Sahay M, et al. 2017 Diabetes and Anemia: International Diabetes Federation (IDF) - Southeast Asian Region (SEAR) position statement. Diabetes Metab. Syndr. 11 Suppl 2 S685–S695Google Scholar
  22. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF and Egan JM 2000 Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 741–748CrossRefGoogle Scholar
  23. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M and Portha B 2002 Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 1443–1452CrossRefGoogle Scholar
  24. Tu P, et al. 2015 Expression of CTB-10xrolGLP-1 in E. coli and its therapeutic effect on type 2 diabetes. Curr. Pharm. Biotechnol. 16 564–572CrossRefGoogle Scholar
  25. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J and Montrose-Rafizadeh C 1995 Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046–38 cells. Endocrinology 136 4910–4917CrossRefGoogle Scholar
  26. Wideman RD, Yu IL, Webber TD, Verchere CB, Johnson JD, Cheung AT and Kieffer TJ 2006 Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl. Acad. Sci. USA 103 13468–13473CrossRefGoogle Scholar
  27. Wu ZQ, Jia NB, Li N, Ma BC and Li MG 2009 Construction of Saccharomyces cerevisiae strain stably expressing a fusion protein containing ten tandem recombinant human glucagon-like peptide-1 analogues. Chem. Res. Chin. Univ. 25 882–886Google Scholar
  28. Zhang M, Lv XY, Li J, Xu ZG and Chen L 2008 The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp. Diabetes Res. 2008 1–9CrossRefGoogle Scholar
  29. Zhang Y, et al. 2013 Expression of rolGLP-HV in E. coli and its dual-function for the treatment of diabetes and thrombosis. Int. J. Peptide Res. Therap. 19 257–263CrossRefGoogle Scholar

Copyright information

© Indian Academy of Sciences 2019

Authors and Affiliations

  • Pingzhe Jiang
    • 1
    • 2
  • Chao Ma
    • 2
  • Junfeng Hao
    • 2
  • Yike Han
    • 2
  • Minggang Li
    • 2
    Email author
  1. 1.Liaoning Ocean and Fisheries Science Research InstituteDalianChina
  2. 2.Key Laboratory for Bioactive Materials of the Ministry of Education, Institute of Molecular Biology, College of Life ScienceNankai UniversityTianjinChina

Personalised recommendations